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Leptin activates multiple signaling pathways in cells, includ-
ing the phosphatidylinositol 3-kinase pathway, indicating a
degree of cross-talk with insulin signaling. The exact mecha-
nisms by which leptin alters this signaling pathway and how it
relates to functional outputs are unclear at present. A previous
study has established that leptin inhibits the activity of the phos-
phatase PTEN (phosphatase and tensin homolog deleted on
chromosome 10), an important tumor suppressor and modifier
of phosphoinositide signaling. In this studywedemonstrate that
leptin phosphorylates multiple sites on the C-terminal tail of
PTEN in hypothalamic and pancreatic-cells, an action not repli-
cated by insulin. Inhibitors of the protein kinases CK2 and glyco-
gen synthase kinase 3 (GSK3) block leptin-mediated PTEN phos-
phorylation. PTEN phosphorylation mutants reveal the critical
role these sites play in transmission of the leptin signal to F-actin
depolymerization. CK2 and GSK3 inhibitors also prevent leptin-
mediatedF-actindepolymerizationandconsequentATP-sensitive
K channel opening. GSK3 kinase activity is inhibited by insulin
but not leptin in hypothalamic cells. Both hormones increase
N-terminal GSK3 serine phosphorylation, but in hypothalamic
cells this action of leptin is transient. Leptin, not insulin, increases
GSK3 tyrosine phosphorylation in both cell types. These results
demonstrate a significant role for PTEN in leptin signal transmis-
sion and identify GSK3 as a potential important signaling node
contributing to divergent outputs for these hormones.
Efficient signaling by leptin and insulin is essential for the
maintenance of body energy homeostasis, with disruptions in
these processes strongly associated with diabetes and obesity
(1, 2) and, at least for insulin, neurodegenerative disorders such
as Alzheimer disease (3, 4). In recent years there has been a
significant increase in understanding the intracellular signaling
processes associated with the actions of insulin on a wide vari-
ety of cell types (5). However, our knowledge of leptin signaling
is less advanced, with most studies indicating that leptin and
insulin share many signaling intermediates in common, often
leading to similar cellular outcomes (6, 7). In particular, signal-
ing through the STAT (signal transducers and activators of
transcription), mitogen-activated protein kinase, and PI3K3
pathways have been reported extensively in numerous cell
types for both leptin and insulin (5, 8).
Nevertheless, leptin and insulin can cause differing and
sometimes opposing cellular outputs, even on the same cell
type. This is demonstrated in hypothalamic neurons, where
electrophysiological or imaging studies show differential out-
comes for leptin and insulin action (9–11). Thus, although
superficially leptin may utilize the same signaling pathways as
insulin, the exact nature of the leptin-induced signaling inter-
mediates and their interplaywith one another andwith individ-
ual effectors is still relatively unknown. Recently, it was demon-
strated that although leptin, like insulin, raises PtdIns(3,4,5)P3
levels in hypothalamic cells, the mechanism underlying the in-
crease by leptin differs from that of insulin. Whereas insulin
increased PI3K activity, leptin had little effect on PI3K activity.
Instead, leptin inhibited the lipid and protein phosphatase,
PTEN, which resulted in increased PtdIns(3,4,5)P3 levels in the
presence of active PI3K (12). Previously, PI3K-dependent leptin
signaling had been shown to open ATP-sensitive (KATP) chan-
nels in rat hypothalamic neurons (13) and in rat and mouse
insulin-secreting cells (12, 14, 15), resulting in cell hyperpolar-
ization and inhibition of firing. KATP activation by leptin is
dependent on actin depolymerization in both cell types (12–
15). The connection between leptin-driven PI3K activity, actin
re-modeling, and KATP opening appears not to be due simply to
increased PtdIns(3,4,5)P3 but may also require coincident inhi-
bition of PTEN protein and lipid phosphatase activity through
increased PTEN phosphorylation (12).
In this study we have focused on the mechanisms by which
leptin alters PTEN phosphorylation in hypothalamic and insu-
lin-secreting cells. The biological activity of PTEN toward ani-
onic lipid substrates is considered to be dependent on its phos-
phorylation status at various residues between Ser-362 and
Ser-385, located in the PTEN C-terminal tail (Fig. 1A), with
phosphorylation maintaining PTEN in an inactive state (16).
The major sites of phosphorylation are Ser-370 and Ser-385
(17, 18), with significant phosphorylation at a cluster of sites
(Ser-380, Thr-382, and Thr-383) close to Ser-385.Mutations of
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the cluster site residues have significant effects on PTEN stabil-
ity andmembrane and protein binding (17, 19, 20). It is thought
that PTEN is constitutively phosphorylated and not linked to
physiological signaling events such as stimulation of cells with
insulin or growth factors (21, 22). However, we previously dem-
onstrated that leptin stimulation of hypothalamic cells reduced
PTEN phosphatase activity and increased PTEN phosphoryla-
tion at the cluster site (12). This increased phosphorylation was
sensitive to inhibition of protein kinase CK2, previously impli-
cated as the main kinase phosphorylating PTEN at these resi-
dues (17, 18). CK2 has also been reported to phosphorylate
PTEN at Ser-370 and Ser-385 (Fig. 1A) using in vitro kinase
assays (17, 23), resulting in a 30% depression of PTENphospha-
tase activity (18). In addition, GSK3 has been reported to
phosphorylate PTEN at Ser-362 and Thr-366 in human embry-
onic kidney 293T cells, with Thr-366 phosphorylation reducing
the biological activity of PTEN.
Consequently, we have assessed whether leptin mediates
phosphorylation of PTEN at Ser-370, Ser-385, and Thr-366 in a
CK2- and GSK3-dependent manner and further examined the
contribution of Ser-370 and Thr-366 to downstream events
such as actin re-organization and KATP channel opening using
hypothalamic and insulin-secreting cells.
EXPERIMENTAL PROCEDURES
Cell Culture and Islet Isolation—The mouse hypothalamic
cell line N29/4 was cultured as previously described (24).
MIN6 cells (obtained with permission from Jun-ichi Miyazaki,
Osaka University) were used between passages 24 and 30 and
grown in Dulbecco’s modified Eagle’s medium containing 25
mM glucose and supplemented with 12.5% heat-inactivated
fetal calf serum, 4mM L-glutamine, 100M 2-mercaptoethanol,
and 1% penicillin and streptomycin in a humidified atmosphere
of 95% air and 5%CO2.Wild-typeC57Bl/6mice (20–25 g)were
used for islet isolation and killed by cervical dislocation imme-
diately before the islet isolation procedure. All animal proce-
dures conformed to the UK Animals (Scientific Procedures)
Act 1986 and were approved by our institutional ethical review
committee. Pancreatic islets were isolated from mice under
sterile conditions, and isolated cells were cultured as described
previously (12).
Cell Transfection, Staining, and Actin Analysis—N29/4 cells
were plated in 6-well plates at 40% confluence 24 h before trans-
fection. 5 l of Lipofectamine (Invitrogen) and 2 g of PTEN
DNA were mixed with 100 l of serum-free Opti medium,
incubated at room temperature for 20 min to form the trans-
fection complexes, and diluted with 500 l of culture medium.
The mixture was applied to the cells, left overnight at 37 °C,
replaced with culture medium, and incubated for 48 h before
use. In experiments where wild-type and mutant PTEN con-
structs were overexpressed, F-actin or PtdIns(3,4,5)P3 levels
were determined from 60 cells for control and each treatment
from a total of 4 experiments (comparing transfected cells, as
determined by PTEN antibody staining, with control cells).
Similarly, 72 cells were examined from 4 experiments to meas-
ure F-actin in control and leptin with or without CT99021
and/or 2-dimethyl-amino-4,5,6,7-tetrabromo-1H-benzimida-
zole (DMAT). Cells were treated with DMAT (Calbiochem)
and/or CT99021 (25) in normal saline (135 mM NaCl, 5 mM
KCl, 1 mM MgCl2, 1 mM CaCl2, 10 mM HEPES, and 0.2% BSA,
pH 7.4) for 20 min before challenge with leptin or saline in the
continuous presence of inhibitor for 60 min before fixing as
described previously (13). For staining, cells were washed in
phosphate-buffered saline (PBS), permeabilized in PBS, 0.5%
Triton X-100 for 10 min, rinsed, blocked with 20% goat serum
(Sigma), and incubated with rhodamine-conjugated phalloidin
or 2 units ml1 Alexa 488-phalloidin (Molecular Probes) for
90–120 min. Immunocytochemical staining was performed as
described previously (13) using a monoclonal antibody against
PTEN (Chemicon) or PtdIns(3,4,5)P3 (Molecular Probes). The
secondary antibodies were Cy3 or fluorescein isothiocyanate-
conjugated anti-mouse IgG (Jackson ImmunoResearch). Fluo-
rescence-labeled proteins or lipids in cells were observed with a
63 oil objective, and images were acquired by confocal
microscopy (Zeiss LSM 510). For quantitative analysis of F-ac-
tin and PtdIns(3,4,5)P3 levels, Aida/two-dimensional densito-
metry was used to measure pixel intensity of defined areas of
transfected, treated, and control cells. After subtraction of
background, intensity values for treated cells were expressed as
a ratio of control cell intensity.
Western Blotting—N29/4 and MIN6 cells, grown in 6-well
plates, were exposed to normal saline for 30 min before treat-
ment with leptin, insulin, or saline in the presence and absence
of LY294002 (Sigma), DMAT, or CT99021 for the required
time (inhibitors added 20–30 min before challenge). Protein
isolation, content, immunoblotting, and analysis procedures
were as previously described (13). PTEN and phospho-PTEN
antibodies, Ser-380/Thr-382/Thr-383were fromCell Signaling
(1:5000), Ser-385 was from BIOSOURCE (1:500), and Ser-370
and Thr-366 were from Nick Leslie (1:500). phosphorylated
(p)-PKB (Ser-473) and p-GSK3 (Ser-9/Ser-21) were obtained
from Cell Signaling and used at 1:1000. p-GSK3 (Tyr-216/Tyr-
279), PKB, and GSK3 antibodies (all polyclonal) were obtained
from BD Transduction Laboratories and used at 1:2500
(p-GSK3) and 1:1000 (PKB and GSK3). Monoclonal anti -ac-
tin antibody (used at 1:10000) was fromMP Biochemicals. Pro-
tein bands on gels were quantified by densitometry, where total
density was determined with respect to constant area, back-
ground was subtracted, and average relative band density was
calculated.
Immunoprecipitation and Assay of GSK3—Cell extracts (0.5
mg) were incubated with protein G-Sepharose conjugated to
2.5 mg of anti-GSK3/ antibody, Upstate Biotechnology, Inc.
(Lake Placid, NY) for 1 h at 4 °C on a shaking platform. The
immunocomplexes were pelleted and washed with 1 ml of lysis
buffer containing 0.5MNaCl and twice with 1ml of assay buffer
(50mMTris-HCl, pH7.5, 150mMNaCl, 0.03% (v/v) Brij-35, and
0.1% (v/v) -mercaptoethanol). The immunoprecipitated
GSK3 was incubated at 30 °C for 20 min in a total volume of 50
ml containing 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 0.03%
(v/v) Brij-35, 0.1% (v/v) -mercaptoethanol, 10 mM MgCl2, 0.1
mM [-32P]ATP (0.5  106 cpm/nmol), and 30 mM phospho-
glycogen synthase 2 peptide (available from Upstate). Radiola-
beled peptide produced was separated from unreacted ATP by
binding to P81 paper and washing in 75 mM H3PO4 before
counting in 2 ml of scintillant. One unit of kinase activity is
Leptin and PTEN Phosphorylation
9332 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284 • NUMBER 14 • APRIL 3, 2009
defined as the amount that catalyzes the phosphorylation of
1 nmol of substrate in 1 h.
Electrophysiology—Mouse cultured -cells were superfused
at room temperature (22–25 °C) with normal saline. Whole-
cell current and voltage clamp recordings were used tomonitor
membrane potential and macroscopic current, respectively,
using an Axopatch 200B amplifier. Whole-cell experiments
were maintained in current-clamp mode to monitor the cell
resting membrane potential, with short excursions into voltage
clampmode to examinemacroscopic current-voltage relations.
In voltage-clamp recordings the membrane potential was held
at 70- and 20-mV steps of 2 s duration, with 20 ms between
pulses applied (range of voltages,160 to40mV).Whole cell
voltage clamp data were analyzed using pCLAMP 8.2 software
(Molecular Devices). Current clamp data were recorded and
stored onto digital audio tapes and replayed for analysis and
illustration on a Gould TA240 chart recorder. Recording elec-
trodes were pulled from borosilicate glass and had resistances
of 5–10 megaohms when filled with pipette solution, which
comprised 140 mM KCl, 5 mM MgCl2, 3.8 mM CaCl2, 3 mM
MgATP, 10 mM EGTA, 10 mM HEPES, pH 7.2 (free [Ca2] of
100 nM). Application of drugs was made via the bath perfusion
system except for DMAT and the GSK3 inhibitors, which were
present in the pipette solution.
Statistical Analysis—Data are presented as the means  S.E.
unless otherwise stated. All statistical analyses were performed
using analysis of variance, one sample
t test, Student’s paired or unpaired t
tests. A probability level of 0.05 was
considered significant.
RESULTS
We used the leptin- and insulin-
sensitive hypothalamic cell line
N29/4 (12, 24) to examine PTEN
phosphorylation at Thr-366, Ser-370,
and Ser-385 (Fig. 1A) on stimulation
with leptin (10 nM) or insulin (10
nM). Leptin rapidly (5 min)
increased the level of p-PTEN at all
three sites (Fig. 1B), an action sus-
tained for at least 60 min for each
site (data not shown). This leptin-
mediated increase in p-PTEN was
unaffected by the presence of the
PI3K inhibitor, LY294002 (10 M;
n  6 for each; Fig. 1B). Previous
studies indicated that the cluster
site, Ser-385 and Ser-370, may be
phosphorylated by protein kinase
CK2 (17, 18, 23), and Thr-366 may
be phosphorylated by GSK3 (23).
Consequently, we examined leptin
phosphorylation of Thr-366, Ser-
370, and Ser-385 PTEN residues in
the absence and presence of DMAT
(a CK2 inhibitor (26, 27) and
CT99021 (a specific GSK3 inhibitor
(28, 29)). DMAT (10 M) prevented leptin from phosphoryl-
ating Ser-370 and Ser-385 but not Thr-366 in N29/4 cells (Fig.
1, B andC). Conversely, leptin phosphorylation of Thr-366 was
prevented byCT99021 (2M), whereas phosphorylation of Ser-
370 and Ser-385 was unaffected by this inhibitor (Fig. 1, B and
C). In contrast, 10 nM (Fig. 1D) or 50 nM (data not shown)
insulin hadno effect onp-PTEN levels inN29/4 cells atThr-366
or Ser-370 residues, with the Ser-385 site not tested.
Leptin re-organization of the actin cytoskeleton is dependent
on PI3K activity and inhibition of the lipid and protein phos-
phatase activity of PTEN. Overexpression of cluster site
p-PTEN mutants demonstrated that phosphorylation at this
site was required to limit PTEN phosphatase activity and pre-
vent leptin-induced F-actin depolymerization (12). Accord-
ingly, we have examined whether phosphorylation of PTEN at
Ser-370 and/or Thr-366 is also required for transmission of the
leptin signal to F-actin. First, we sought to determine whether
phosphorylation of Thr-366 or Ser-370 altered the activity of
PTEN in cells by overexpression of PTENmutants with alanine
or aspartic acid substitutions. PtdIns(3,4,5)P3 and F-actin levels
were assessed by staining with a monoclonal PtdIns(3,4,5)P3
antibody and Alexa 488-conjugated phalloidin respectively,
after transfection of PTENmutants into N29/4 cells. In control
experiments overexpression of wild-type PTEN had no effect
per se but prevented leptin from decreasing F-actin (Fig. 2A).
Overexpression of T366A PTEN or S370A PTEN reduced
FIGURE 1. Inhibitors of CK2 and GSK3 reduce leptin-mediated phosphorylation of PTEN in N29/4 cells.
A, schematic representation of PTEN. The sequence of amino acids for part of the C-terminal tail domain is
shown, with the main phosphorylation sites denoted in bold, and the putative phosphorylating kinase shown
below. B, phosphorylated PTEN levels in N29/4 cells using the phospho-specific PTEN antibodies indicated
under non-stimulated conditions (C), in response to 10 nM leptin alone (L), and in the presence of 10 M DMAT
(LD), 2 M CT99021 (LCT), and 10 M LY294002 (LLY). C, the bar graphs show mean normalized levels of
phosphorylated PTEN at Ser-385, Ser-370, and Thr-366 under non-stimulated conditions (C) and for leptin in
the absence (L) and presence of DMAT (LD) and CT99021 (LCT; n  6 for each). D, bar graphs showing mean
normalized levels of phosphorylated PTEN at Thr-366 and Ser-370 under non-stimulated conditions (C) and
after stimulation of N29/4 cells for 5 or 30 min with 10 nM insulin.
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PtdIns(3,4,5)P3 levels (data not shown), indicative of enhanced
PtdIns(3,4,5)P3 phosphatase activity, did not affect F-actin in
the absence of leptin and inhibited leptin-induced F-actin
reduction (Fig. 2, A and B). In contrast, overexpression of
T366D PTEN or S370D PTEN increased PtdIns(3,4,5)P3 levels
(Fig. 2C). The presence of the 366D PTEN mutant in N29/4
cells decreased F-actin levels in the absence of leptin in a PI3K-
dependent manner (Fig. 2D). Surprisingly, overexpression of
S370D PTEN, although increasing PtdIns(3,4,5)P3, did not per
se alter F-actin staining in the absence of leptin nor occlude the
effect of leptin on F-actin (Fig. 2E). This action of S370D PTEN
indicates, as observed previously
(12), that increasing cellular
PtdIns(3,4,5)P3 levels alone is not a
predictor or indeed sufficient to ini-
tiate PTEN-dependent downstream
signaling events such as F-actin
depolymerization.
The dependence of F-actin depo-
lymerization by leptin on the phos-
phorylation status of the cluster (12)
and Thr-366 sites led us to explore
whether this action of leptin was
sensitive to CK2 and/or GSK3 inhi-
bition. The presence of the GSK3
inhibitor, CT99021 (2 M) or the
CK2 inhibitor DMAT (10M) alone
had no effect on F-actin (data not
shown). Leptin decreased the mean
F-actin level, and in the presence of
CT99021 this was significantly
reduced (Fig. 2F). The combined
presence of CT99021 and DMAT
inhibited F-actin depolymerization
by leptin significantly more than
CT99021 alone but did not com-
pletely occlude leptin from affecting
F-actin levels (Fig. 2F). Neverthe-
less, the presence of the GSK3 and
CK2 inhibitors at concentrations
that significantly reduced PTEN
phosphorylation also significantly
reduced the ability of leptin to depo-
lymerize F-actin.
Phosphorylation of PTEN in
-Cells and KATP Activation—It
was previously demonstrated that
KATP channel opening and hyper-
polarization of mouse pancreatic
-cells by leptin could be inhibited
by the lipid phosphatase dead
G129E PTEN mutant and mim-
icked by the dual lipid and protein
phosphatase dead C124S PTEN
mutant (12). This is consistent
with inhibition of PTEN lipid and
protein phosphatase activity for
the successful transmission of the
leptin signal to KATP channels in -cells. As leptin has not
been shown to alter p-PTEN status in -cells, we used MIN6
-cells to explore this action of leptin. Although the effects
of leptin on p-PTEN were not as robust as observed for
N29/4 cells, leptin (10 nM) rapidly (1 min) increased phos-
phorylation of the cluster site, Ser-370 and Thr-366, actions
sustained for at least 30 min in each case (Fig. 3, A and B).
Insulin (10 nM) had no effect on PTEN phosphorylation lev-
els at any of these sites over this time period (Fig. 3, A–C).
The CK2 inhibitor DMAT (2 M) inhibited leptin-mediated
PTEN phosphorylation at Ser-370 and Thr-366, whereas the
FIGURE 2. Effect of PTEN phosphorylation mutants on PtdIns(3,4,5)P3 and F-actin levels in N29/4 cells.
Wild-type PTEN and T366A PTEN (A) and S370A PTEN (B) were overexpressed in N29/4 cells (upper panels, Cy3
secondary antibody on cells treated with monoclonal PTEN antibody) and F-actin visualized with Alexa 488-
phalloidin (lower panels) with and without stimulation by 10 nM leptin. Note that untransfected cells in the
leptin (L)-treated group are not easily visible in the right lower panels due to leptin-mediated F-actin depoly-
merization. Bar graphs showing mean levels of F-actin after treatment of N29/4 cells  overexpression of PTEN
or T366A PTEN (A) or S370A PTEN (B) with 10 nM leptin. Data are shown as a ratio of control, untreated cells.
C, PtdIns(3,4,5)P3 levels in N29/4 cells transfected with T366D PTEN or S370D PTEN were investigated using a
PtdIns(3,4,5)P3 antibody. The bar graph shows mean levels of PtdIns(3,4,5)P3 (as a ratio of control) in N29/4 cells
after treatment with these PTEN phosphorylation mutants. D and E, F-actin levels were visualized (lower panels)
in N29/4 cells transfected (upper panels) with T366D PTEN (D) or S370D PTEN (E) in the absence (left) and
presence (right) of 10 M LY294002 (LY, D) or 10 nM leptin (E). The bar graphs show mean levels of F-actin after
treatment of N29/4 cells overexpressing T366D PTEN (D) or S370D PTEN (E). Data are shown as a ratio of control,
untreated cells. F, cellular F-actin levels in the absence or presence of 10 nM leptin and in cells pretreated with
2 M CT99021 alone (CT) or in combination with 10 M DMAT (D) before leptin challenge. Note that F-actin is
visualized in this series of experiments with rhodamine-conjugated phalloidin. The bar graph denotes mean
levels of F-actin-treated cells. Data are shown as the ratio of control, untreated cells. Values represent the
mean  S.E. for 3– 4 experiments per group. *, p  0.05 compared with the appropriate labeled control for each
treatment. Scale bars, 10 M. PIP3, PtdIns(3,4,5)P3.
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GSK3 inhibitor CT99021 (10 M) inhibited phosphorylation
at Thr-366 only (Fig. 3D).
Consequently, we predicted that the F-actin reduction and
opening of KATP channels by leptin (12, 13) would be suscepti-
ble to inhibition of CK2 andGSK3. Therefore, we examined the
ability of leptin to hyperpolarize the membrane potential and
activate KATP currents in whole-cell current and voltage clamp
recordings, respectively, frommouse primary cultured pancre-
atic -cells in the absence and pres-
ence of DMAT and various GSK3
inhibitors. In control experiments
-cells were dialyzed with an elec-
trode solution containing 3 mM
ATP, which resulted in a mean
membrane potential of 41.8  1.5
mV (n  22) under current clamp
conditions. Application of leptin (10
nM) resulted in a slowly developing
hyperpolarization (Fig. 4A) to a
mean value of69.4 1.6 mV (n 
22, p  0.05), which was reversibly
inhibited (to 34.5  1.9 mV; n 
17, p 0.05) by the sulfonylurea tol-
butamide (100 M). Voltage clamp
analysis (Fig. 4A) showed that leptin
increased the mean cell slope con-
ductance from 0.73 0.11 to 1.62
0.22 nanosiemens (n  19; p 
0.05), an action reduced by tolbuta-
mide to 0.42  0.04 nanosiemens
(n  14; p  0.05), indicating that
FIGURE 3. Leptin increases PTEN phosphorylation in MIN6 pancreatic -cells. A, phosphorylated PTEN
levels in MIN6 cells using the phospho-specific PTEN antibodies indicated (cluster site, Ser-370 and Thr-366), in
response to 10 nM leptin or 10 nM insulin for the indicated times (minutes). B, the bar graph shows mean
normalized levels of phosphorylated PTEN at the cluster phosphorylation site (380/2/3) for untreated cells and
for cells stimulated with leptin (filled bars; n  6) and insulin (open bars; n  8) up to 30 min (*, p  0.05, versus
control (C) or insulin). C, bar graph shows the mean normalized levels of phosphorylated Thr-366 PTEN after
stimulation with 10 nM insulin for 5 and 30 min. D, bar graphs showing mean normalized levels of phosphoryl-
ated Thr-366 PTEN and Ser-370 PTEN under non-stimulated conditions (C) and after stimulation with 10 nM
leptin in the absence (L) and presence of DMAT (LD) and CT99021 (LCT; n  7 for each). *, p  0.05.
FIGURE 4. Activation of KATP channels in mouse pancreatic -cells by leptin is occluded by the presence of CK2 or GSK3 inhibitors. Representative
whole-cell current clamp recordings from a mouse cultured -cell dialyzed with an electrode solution containing 3 mM ATP. In this and subsequent panels the
trace begins 2 min after obtaining the recording configuration. Leptin (10 nM), tolbutamide (Tolb, 100 M), or diazoxide (Dzx, 200 M) were applied for the
time indicated on each trace (A–E). Cont, control. The action of leptin on -cell membrane potential was determined in the absence (A) and presence of 10 M
DMAT (B), 2 M CT99021 (C), 10 M kenpaullone (D), and 2 M AR-A0144 –18 (E) added to the electrode solution and, hence, cell interior. The bar graphs to the
right of each trace denote the mean slope conductance, determined from voltage clamp current-voltage relations in the absence and presence of leptin. In
control cells (A) the hyperpolarization and increased slope conductance induced by leptin are inhibited by the presence of tolbutamide. For drug-treated cells
leptin has no effect on mean cell conductance, although in each case application of 200 M diazoxide hyperpolarizes the cells, which is associated with a
significant increase in slope conductance. *, p  0.05, compared with control.
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the increase in current responsible for the augmented slope
conductance and -cell hyperpolarization by leptin is due to
KATP channel opening (14, 15, 30). The presence of DMAT (10
M) in the electrode solution (and, therefore, cell interior)
resulted in a mean resting membrane potential of 44.8  3.4
mV (p  0.05 compared with control). Subsequent addition of
leptin caused a small, insignificant (p 0.05) hyperpolarization
to 52.4  8.4 mV (n  5; Fig. 4B), which was significantly
different (p  0.05) from the control leptin response. Voltage
clamp analysis showed that DMAT also prevented leptin from
increasing the -cell mean slope conductance (Fig. 4B). The
KATP channels were operational in the presence of DMAT as
-cells were readily responsive (Fig. 4B) to the direct-acting
KATP activator, diazoxide (200 M), which caused hyperpolar-
ization to 75.2  1.7 mV (p  0.05) and increased slope con-
ductance from0.82 0.07 to 3.1 0.8 nanosiemens (n 5; p
0.05). CT99021 (2 M), in the electrode solution, resulted in a
mean -cell membrane potential of 41.5  3.3 mV. Applica-
tion of leptin (Fig. 4C) caused hyperpolarization to51.5 4.1
mV, which although less than the control leptin response, was
significantly different (n  5, p  0.05) from the mean resting
potential before leptin challenge. However, voltage clamp anal-
ysis showed that in the presence of CT99021 leptin did not
significantly increase the -cell slope conductance (Fig. 4C). As
a small, but significant hyperpolarization of -cells was elicited
by leptin in the presence of CT99021, we decided to confirm
that GSK3 inhibition does occlude leptin-mediated -cell
hyperpolarization and increase in KATP current. Consequently,
we examined the effects of the GSK3 inhibitors, AR-A0144-18
(28, 31) and kenpaullone (29) on leptin-induced opening of
KATP. The presence of AR-A0144-18 (2M) or kenpaullone (10
M) in the electrode solution did not alter (p  0.05) -cell
membrane potential (40.4  1.6 mV and 35.2  2.1 mV,
respectively) compared with control recordings. Leptin (10 nM)
caused a small hyperpolarization of the -cells for both AR-
A014418 (to 51.8  6.4; n  5) and kenpaullone (to 45.5 
4.6 mV; n  6), which was not significant (p  0.05) for either
inhibitor (Fig. 4, D and E). Voltage clamp analysis confirmed
that the presence of either GSK3 inhibitor prevented an
increase in slope conductance by leptin (Fig. 4, D and E).
Diazoxide (200 M), in contrast, reversibly hyperpolarized
-cells in the presence of each GSK3 inhibitor (Fig. 4, C–E,
CT99021, to 73.0  2.2 mV (n  5; p  0.05), AR-A014418
to 72.4  4.1 mV (n  5, p  0.05), and kenpaullone, to
72.3  2.4 mV (n  6, p  0.05) and significantly increased
the mean slope conductance to values comparable for con-
trol -cells (p  0.05).
Phosphorylation and Kinase Activity of GSK3—These results
taken together with those of Ning et al. (12) indicate that leptin
inhibits PTEN phosphatase activity via phosphorylation at
multiple sites on the C terminus of PTEN, which results in
increased PtdIns(3,4,5)P3 levels, actin restructuring, and KATP
activation. These events appear to be mediated through CK2-
and GSK3-dependent mechanisms. However, the dependence
on PTEN Thr-366 phosphorylation on GSK3 activity and con-
sequent influence on downstream signaling events such as
KATP channel regulation gives rise to a quandary. Leptin stim-
ulation of rat arcuate increases PKB phosphorylation with sub-
sequent GSK3 phosphorylation at Ser-9/Ser-21 (13), actions
also reported for leptin on mouse skeletal muscle cells (32, 33),
mouse cortical neurons (34), and MCF-7 breast cancer cells
(35). These latter actions of leptin replicate those of insulin,
which increases PI3K activity and raises PtdIns(3,4,5)P3 levels
with subsequent increased PKB andGSK3 phosphorylation (5).
Importantly, the phosphorylation of GSK3 at these serine resi-
dues by PKB is associated with reduced kinase activity (36, 37).
This outcome is inconsistent with the requirement for active
GSK3 causing phosphorylation of PTENThr-366 allowing sub-
sequent downstream signaling. Indeed, leptin (10 nM) increases
the phosphorylation of PKB (Ser-473) andGSK3 (Ser-9/Ser-21)
in N29/4 hypothalamic cells (Fig. 5A), although this is not well
sustained in the hypothalamic cells, as previously reported for
rat arcuate (13) and mouse muscle (32, 33). Insulin (10 nM)
induced a sustained rise in PKB (Ser-473) andGSK3 (Ser-9/Ser-
21) phosphorylation in N29/4 cells (Fig. 5B). Similar results
were obtained for MIN6 -cells, although in this case both lep-
tin (10 nM) and insulin (10 nM) produced sustained increases
(Fig. 5, C and D) in the levels of phosphorylated PKB (Ser-473)
andGSK3 (Ser-9/Ser-21). These results are ostensibly inconsis-
tent with the view that leptin signaling to actin and KATP chan-
nels requires GSK3-dependent phosphorylation and inhibition
of PTEN activity. However, GSK3 also has a tyrosine residue in
the activation loop of the enzyme (Tyr-216 in GSK3 and Tyr-
279 in GSK3), the phosphorylation of which is important for
GSK3 activity (38, 39). Most studies conclude that this site is
not physiologically regulated by growth factors or cytokines
(40). Insulin (10 nM) did not affect GSK3 Tyr-216/Tyr-279
phosphorylation levels in either N29/4 cells (Fig. 6A) or MIN6
-cells (Fig. 6C). In contrast, leptin (10 nM) rapidly increased
GSK3 phosphorylation at Tyr-216/Tyr-279 in N29/4 (Fig. 6B),
and MIN6 (Fig. 6D) cells, which was sustained for at least 1 h.
Thus, in contrast to insulin, which increases phosphorylation of
GSK3 serine sites only (consistent with kinase inhibition), lep-
tin increases the phosphorylation level of both serine and tyro-
sine sites on GSK3. To define the outcome of this dual phos-
phorylation of GSK3, we examined the effects of leptin (10 nM)
and insulin (50 nM) onGSK3 activity inN29/4 cells. Stimulation
of N29/4 cells by insulin for 30 min results in a substantial
inhibition of GSK3 activity, as expected from increased PKB
activity causing GSK3 Ser-9/Ser-21 phosphorylation. In con-
trast, stimulation of N29/4 cells with leptin (10 nM) for 30 min,
a time when PTEN phosphorylation is increased,
PtdIns(3,4,5)P3 levels are high, F-actin is depolymerized, and
-cells are hyperpolarized, results in maintained GSK3 activity
(Fig. 6E). This outcome is consistent with the finding that,
although both hormones increase GSK3 Ser-9/Ser-21 phos-
phorylation levels, leptin, but not insulin, also increases GSK3
Tyr-216/Tyr-279 phosphorylation.
DISCUSSION
Leptin phosphorylation of PTEN at the cluster site is CK2-
dependent and leads to inhibition of PTEN phosphatase activ-
itywith a consequent increase in PtdIns(3,4,5)P3 levels inN29/4
cells (12). Here, we show that leptin increases PTEN phospho-
rylation at three further sites, Thr-366, Ser-370, and Ser-385 in
N29/4 cells. We also show that leptin increases p-PTEN at the
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cluster site, Thr-366 and Ser-370, in
MIN6 pancreatic -cells. As dem-
onstrated for the cluster site (12),
phosphorylation of PTEN in N29/4
cells at Thr-366 and Ser-370 is
important for transfer of the leptin
signal downstream to cause F-actin
depolymerization. Leptin-mediated
reduction in F-actin levels was pre-
viously shown to be dependent on
basal PI3K activity and inhibition of
both lipid and protein phosphatase
activity of PTEN (12). Correspond-
ingly, overexpression of the PTEN
phosphorylation site mutants,
S370A PTEN and T366A PTEN, in
N29/4 cells occluded leptin-driven
reduction in F-actin. The Thr-366
and Ser-370 alanine and aspartic
acid PTEN mutants, when overex-
pressed in N29/4 cells, alter
PtdIns(3,4,5)P3 levels exactly as
reported for the cluster site
mutants. This outcome does not
agree with in vitro assays, which
show no alteration in enzyme activ-
ity associated with these mutants
(41), unlike the corresponding
mutations of the cluster site resi-
dues (12). Thus, S370D and T366D
both raised PtdIns(3,4,5)P3 levels,
FIGURE 5. Leptin and insulin increase PKB and GSK3 serine phosphorylation in N29/4 and MIN6 cells. PKB (Ser-473 (S)) and GSK3 (Ser-9/Ser-21) phos-
phorylation was determined in N29/4 (A and B) and MIN6 (C and D) cells, stimulated with 10 nM leptin (A and C), or 10 nM insulin (B and D) for the indicated times
(minutes). The bar graphs below each set of blots show mean normalized p-PKB and p-GSK3 levels for untreated cells and cells stimulated with leptin (N29/4 (A,
n  9), MIN6 (C, n  6)) or with insulin (N29/4 (B, n  9), MIN6 (D, n  6)). *, p  0.05, compared with control level for each treatment. Cont, control.
FIGURE 6. Leptin, but not insulin, increases GSK3 tyrosine phosphorylation in N29/4 and MIN6 cells. GSK3
(Tyr-216/Tyr-279 (Y)) phosphorylation was determined in N29/4 (A and B) and MIN6 cells (C and D) stimulated
with 10 nM insulin (A and C) or 10 nM leptin (B and D) for the indicated times (minutes). The bar graphs below
each set of blots show mean normalized p-GSK3 for untreated cells and cells stimulated with insulin (N29/4
(A, n  9), MIN6 (C, n  6)) or with leptin (N29/4 (B, n  9), MIN6 (D, n  6). *, p  0.05, compared with control
level for each treatment. E, N29/4 cells were stimulated with either 10 nM leptin or 50 nM insulin for 30 min. The
bar graph denotes the mean normalized GSK3 activity and shows that insulin significantly inhibited GSK3
activity, whereas leptin had no effect on GSK3 activity (n  3 for each). Cont, control.
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indicative of reduced lipid phosphatase activity per se and dom-
inant negative behavior with respect to native PTEN activity.
Interestingly, these mutants produced different outcomes on
F-actin levels and leptin signal transduction. Overexpression of
T366DPTEN per semimicked the effects of leptin by increasing
PtdIns(3,4,5)P3 and inducing F-actin depolymerization in a
PI3K-dependent manner. This replicates the effect of over-
expression of C124S PTEN and D3PTEN (cluster site mutant)
in these cells (12) and is consistent with phosphorylation of the
Thr-366 site reducing PTEN lipid and protein phosphatase
activity. In contrast, overexpression of S370DPTENwas unable
to elicit F-actin depolymerization per se even in the face of
increased cellular PtdIns(3,4,5)P3 levels and did not occlude
leptin-mediated F-actin depolymerization. Consequently,
mimicking phosphorylation by aspartate substitution at Ser-
370 does not exactly replicate the effect of aspartate substitu-
tion at Thr-366 or the cluster phosphorylation site (12), with all
three mutant forms of PTEN increasing PtdIns(3,4,5)P3 levels
but only the latter two reducing F-actin levels. The S370D
PTEN mutant also does not duplicate the action of the lip-
id phosphatase dead, protein phosphatase active, mutant G129E
PTEN.Overexpression ofG129EPTEN inN29/4 cells increases
PtdIns(3,4,5)P3 levels with no reduction in F-actin and prevents
leptin-mediated F-actin depolymerization (12), whereas the
presence of S370D PTEN allows leptin depolymerization of
actin. Our conclusion from these data is that S370D is lipid
phosphatase dead but protein phosphatase active and that lep-
tin inhibits the protein phosphatase activity by phosphorylation
at the Thr-366 and cluster sites, whereas the protein phospha-
tase activity of G129E PTEN cannot be overcome by phospho-
rylation at these sites. Thus, phosphorylation of PTEN at Ser-
370 is adequate to inhibit PTEN lipid phosphatase activity and
increase PtdIns(3,4,5)P3 in N29/4 cells but is not sufficient per
se for efficacious transmission of the leptin signal to F-actin.
A number of phosphorylation sites have been identified
within the PTEN C-terminal tail, with the protein kinase, CK2,
purported to phosphorylate multiple residues, including the
cluster site, Ser-385 and Ser-370, but not Thr-366 (17–19, 23,
41). PTEN protein stability and activity are considered to be
dependent on phosphorylation status of the C-terminal tail (17,
18), with phosphorylation argued to reduce association of
PTEN with the plasma membrane (20, 42, 43). It is presently
unclear what effect leptin-induced phosphorylation will have
on PTEN protein stability, as it has been reported that T366A
and S370A are more stable than wild-type PTEN and GSK3
inhibition increases the stability of wild-type PTEN (41),
whereas alanine mutation of the cluster site results in reduced
protein stability (17, 19). The inhibition of leptin-induced phos-
phorylation of the cluster site (12), Ser-370 and Ser-385, in
N29/4 cells and of the cluster site and Ser-370 inMIN6 cells by
DMAT supports the view that CK2 is the kinase responsible for
phosphorylation at these sites by this hormone. Inhibition of
PI3K had no effect on leptin-mediated phosphorylation at Ser-
370, Ser-385, or Thr-366 in N29/4 cells, indicating no evidence
for PI3K-dependent feedback phosphorylation (44) consistent
with leptin-induced phosphorylation of the cluster site. For
GSK3 to phosphorylate its substrate, the substrate has to be
primed by phosphorylation of a site four or five residues C-ter-
minal of the target Ser/Thr of GSK3 (45, 46). Thus, phospho-
rylation of Ser-370 by CK2 is considered a priming event for
subsequent GSK3 phosphorylation of Thr-366 (23), and inhibi-
tion of GSK3 blocks phosphorylation of PTENonThr-366 (41).
Occlusion of leptin driven-increased p-PTEN on Thr-366 by
the GSK3 inhibitor CT99021 in N29/4 and MIN6 cells agrees
with these findings. Consequently, we expected DMAT to
reduce or inhibit leptin-mediated phosphorylation of Thr-366
in these cells. This was observed for MIN6 pancreatic -cells
but not for the hypothalamic cells, where DMAT prevented
leptin-induced phosphorylation of Ser-370 but not Thr-366.
Thus, either an additional unidentified priming kinase is
responsible or there is sufficient phosphorylation of Ser-370
remaining in DMAT-treated N29/4 cells to allow GSK3 prim-
ing. Interestingly, an in vitro study of PTEN phosphorylation
has shown that phosphorylation of Ser-370 by CK2 is less effi-
cient than that of the cluster site and that GSK3 is capable of
phosphorylating PTEN at Thr-366 without priming, although
at low efficiency (41). Thus, we predicted that inhibition of CK2
and GSK3 would prevent or reduce transmission of the leptin
signal via PTEN to actin filament restructuring and KATP chan-
nel opening. Our results show that the GSK3 inhibitor
CT99021 per se or in combination with DMAT significantly
reduces leptin-mediated F-actin depolymerization. Further-
more, leptin-driven hyperpolarization of pancreatic -cells by
KATP activationwas prevented by the presence ofDMATor any
one of three structurally dissimilar GSK3 inhibitors. This is
consistent with the view that leptin-mediated phosphorylation
of PTENand subsequent inhibition of its phosphatase activity is
a necessary step for signal transmission to KATP channels.
In contrast, insulin does not cause F-actin depolymerization
in N29/4 cells nor does it hyperpolarize pancreatic -cells by
opening KATP channels, and this differential output may be
mediated via PTEN (12). The results presented here indicate a
key role for PTEN Thr-366 phosphorylation via GSK3 activity
for successful transmission of the leptin signal. For this to
occur, GSK3 activity has to be maintained or increased by lep-
tin. However, leptin, like insulin, increases PKB phosphoryla-
tion with the resultant phosphorylation of GSK3 at Ser-9/
Ser-21 consistent with inhibition ofGSK3 activity. Indeed, both
insulin and leptin increased the phosphorylation of GSK3 at
Ser-9/Ser-21 in N29/4 and MIN6 cells. In contrast, leptin, but
not insulin, caused a rapid and sustained increase in GSK3
phosphorylation at Tyr-216/Tyr-279 in both cell types. Phos-
phorylation of GSK3 at this site is considered to be activating
and necessary for functional activity (38). Indeed, direct GSK3
kinase assay showed that insulin stimulation ofN29/4 cells sub-
stantially reduced GSK3 activity, whereas leptin had no effect.
Taken together, the semiquantitative Western blot data show
that insulin significantly alters N-terminal serine phosphoryla-
tion of GSK3, which would reduce its activity toward primed
substrates. However, phosphorylation of PTEN at Thr-366 in
response to leptin does not appear to require priming (phos-
phorylation of this site is unaffected by DMAT), and this may
explain why insulin does not reduce Thr-366 phosphorylation.
In contrast, GSK3 in leptin-treated cells increased phosphate in
Tyr-216/Tyr-279 compared with control or insulin-treated
cells. This is a possible explanation why leptin and not insulin
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induces Thr-366 phosphorylation. However, there are other
ways to regulate GSK3, including protein-protein interaction
(e.g.Wnt signaling) and Thr-380 phosphorylation (e.g. cytokine
signaling) that also require further investigation. Identification
of the kinase (or phosphatase) responsible for the increase in
tyrosine phosphorylation of GSK3 and development of a quan-
titative multiple reaction monitoring liquid chromatography-
mass spectrometric approach for each of the phosphorylation
sites on GSK3 would be required to elucidate the exact mecha-
nism of control by leptin. These subtle signaling differences
downstream of insulin and leptin receptors are likely to con-
tribute to the ability of each to perform their distinct physiolog-
ical actions through modulation of the same signaling
pathways/molecules.
In conclusion, this study has demonstrated that leptin
increases the phosphorylation of PTEN at multiple residues
in a CK2- and GSK3-dependent manner. This action of lep-
tin is required for successful transmission of the leptin signal
to cause cytoskeletal remodeling, the opening of KATP chan-
nels, and subsequent hyperpolarization of membrane poten-
tial. Interestingly, complete loss of PTEN activity in mouse
hypothalamic proopiomelanocortin neurons permanently
activates KATP channels and hyperpolarizes the neurons
resulting in hyperphagia, leptin resistance, and diet-induced
obesity (10). The role of GSK3 in PTEN regulation is intrigu-
ing. Insulin signaling inhibits GSK3 activity, and this may act
via an alteration in PTEN Thr-366 phosphorylation as a neg-
ative feedback loop for leptin signaling in cells. In contrast,
leptin, regardless of whether it stimulates PI3K activity in all
cells or not, by maintaining GSK3 activity may result in a
positive feedback to PI3K signaling in cells. Such interplay
between leptin and insulin signaling in cells may have impor-
tant implications for downstream signaling events. For
example, inhibition of PTEN in peripheral tissues such as
liver, muscle, and fat demonstrate improved insulin sensitiv-
ity and systemic glucose tolerance under normal and high fat
diets (48). Dysregulation of PTEN (lipid and protein phos-
phatase) activity has also been implicated in certain cancers
(49) and neurodegenerative disease (e.g. Parkinson disease
(47)). Thus, modulation of PTEN function plays multiple
and important roles in numerous physiological and patho-
logical phenomena.
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